Definitive chemoradiation followed by stereotactic body radiotherapy boost for inoperable endometrial cancer

被引:3
作者
Dalwadi, Shraddha M. [1 ]
Mantz, Constantine [1 ,2 ]
Tung, Bui [1 ]
Waheed, Nabila [1 ,3 ]
Tran, Danny [1 ,4 ]
Bonnen, Mark [1 ,5 ]
Ludwig, Michelle [1 ]
机构
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] 21st Century Oncol, Ft Myers, FL USA
[3] Ctr Texas, Ft Worth, TX USA
[4] Remote Dosimetry Serv, Houston, TX USA
[5] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA
关键词
SBRT; Endometrial; Brachytherapy; DOSE-RATE BRACHYTHERAPY; INTRACAVITARY BRACHYTHERAPY; CERVICAL-CANCER; RADIATION-THERAPY; CARCINOMA; ANESTHESIA; SOCIETY;
D O I
10.1007/s13566-019-00403-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives For inoperable endometrial cancer (ECA) patients, definitive chemoradiation with stereotactic body radiotherapy (SBRT) boost may be an option. SBRT schedules and dose distributions approximate brachytherapy boost (BB) radiobiologic dosing, while eliminating the need for applicator placement and thus anesthesia. We report toxicity, disease control, and quality-of-life outcomes of a multi-institutional series of SBRT for ECA. Methods Twenty-three patients met the following eligibility criteria: (1) primary ECA, (2) contraindication or refusal of BB, and (3) need for definitive radiation (RT). Prior to SBRT, patients received pelvic RT +/- nodal boost concurrent with cisplatin. SBRT dose of 25.0-35.0 Gy was prescribed to a high-risk clinical target volume (HR-CTV) in 4-5 fractions. Assessments included (1) post-treatment disease surveillance, (2) toxicity using the U.S. National Cancer Institute's CTCAE scales, and (3) quality-of-life using FACT-G. Results Median follow-up was 31 months. BB was infeasible due to medical comorbidities, patient refusal, and technical contraindications (73.9%, 21.7%, and 4.3%, respectively). Most patients were FIGO stage I (60.8%). Mean cumulative dose to high-risk clinical target volume (HR-CTV) was 88.94 Gy (range 75.50-93.83 Gy). Mean SBRT dose to 95% of the planning target volume (PTV) was 32.55 Gy (range 25.00-35.77 Gy), and mean PTV receiving 100% of the dose was 95.29% (range 91.48-99.01%). No patients had grade 2+ long-term gastrointestinal or genitourinary toxicity. Locoregional and distant control was 91.6% at 1 year and 85.4% at 2 year. Only one patient died due to ECA at 6 months. Overall survival was 95.0% at 1 year, 74.0% at 2 year, and 59.2% at 5 year. Patient-reported physical and emotional well-being worsened but improved after the acute phase of treatment. Functional and social/family well-being worsened after 1 month. Conclusion Definitive chemoradiation with SBRT boost is safe and effective alternative when BB is not possible.
引用
收藏
页码:329 / 335
页数:7
相关论文
共 30 条
[1]  
[Anonymous], CANC STAT FACTS UT C
[2]   External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed [J].
Barraclough, Lisa Helen ;
Swindell, Ric ;
Livsey, Jacqueline E. ;
Hunter, Robin D. ;
Davidson, Susan E. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (03) :772-778
[3]  
BERGGREN D, 1987, ANESTH ANALG, V66, P497
[4]   Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer [J].
Cengiz, Mustafa ;
Dogan, Ali ;
Ozyigit, Gokhan ;
Erturk, Ertugrul ;
Yildiz, Ferah ;
Selek, Ugur ;
Ulger, Sukran ;
Colak, Fatma ;
Zorlu, Faruk .
BRACHYTHERAPY, 2012, 11 (02) :125-129
[5]   Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer [J].
Demiral, S. ;
Beyzadeoglu, M. ;
Uysal, B. ;
Oysul, K. ;
Kahya, Y. Elcim ;
Sager, O. ;
Dincoglan, F. ;
Gamsiz, H. ;
Dirican, B. ;
Surenkok, S. .
NEOPLASMA, 2013, 60 (03) :322-327
[6]   Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium [J].
Fishman, DA ;
Roberts, KB ;
Chambers, JT ;
Kohorn, EI ;
Schwartz, PE ;
Chambers, SK .
GYNECOLOGIC ONCOLOGY, 1996, 61 (02) :189-196
[7]   Image-guided radiotherapy for cervix cancer:: High-tech external beam therapy versus high-tech brachytherapy [J].
Georg, Dietmar ;
Kirisits, Christian ;
Hillbrand, Martin ;
Dimopoulos, Johannes ;
Poetter, Richard .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (04) :1272-1278
[8]   Major postoperative complications and survival for colon cancer elderly patients [J].
Grosso, Giuseppe ;
Biondi, Antonio ;
Marventano, Stefano ;
Mistretta, Antonio ;
Calabrese, Giorgio ;
Basile, Francesco .
BMC SURGERY, 2012, 12
[9]   Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer [J].
Guckenberger, Matthias ;
Bachmann, Johanna ;
Wulf, Joern ;
Mueller, Gerd ;
Krieger, Thomas ;
Baier, Kurt ;
Richter, Anne ;
Wilbert, Juergen ;
Flentje, Michael .
RADIOTHERAPY AND ONCOLOGY, 2010, 94 (01) :53-59
[10]   CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy [J].
Haas, Jonathan Andrew ;
Witten, Matthew R. ;
Clancey, Owen ;
Episcopia, Karen ;
Accordino, Diane ;
Chalas, Eva .
FRONTIERS IN ONCOLOGY, 2012, 2